Hormone-replacement therapy increases serum paraoxonase arylesterase activity in diabetic postmenopausal women

Metabolism: Clinical and Experimental

Volumn 50, Issue 3, 2001, Pages 319-324

  Sutherland, Wayne H F ^a   Manning, Patrick J ^a   De Jong, Sylvia A ^a   Allum, Anne R ^a   Jones, Shirley D ^a   Williams, Sheila M ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ARYLESTERASE; CONJUGATED ESTROGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MEDROXYPROGESTERONE ACETATE; PLACEBO;

ABNORMALLY LOW SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; CROSSOVER PROCEDURE; DRUG EFFECT; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HORMONE SUBSTITUTION; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0035083037     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1053/meta.2001.20201     Document Type: Article

References (24)

1. Paraoxonase: Biochemistry, genetics and relationship to plasma lipoproteins
2. Protective effect of high density lipoprotein associated paraoxonase: Inhibition of the biological activity of minimally oxidized low density lipoprotein
3. Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions. PON1 esterase and peroxidase-like activities
4. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man
5. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis
6. Serum paraoxonase after myocardial infarction
7. Serum paraoxonase activity in familial hypercholesterolaemia and insulin dependent diabetes mellitus
8. Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus
9. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins
10. Serum paraoxonase activity and its relationship to diabetic complications in patients with non-insulin-dependent diabetes mellitus
11. Short-term estrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM
12. The writing group for the PEPI trial: Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial
13. Reduced postprandial serum paraoxonase activity after a meal rich in used cooking fat
14. 2+ precipitation procedure for quantification of high density lipoprotein cholesterol
15. Immunoturbidimetric method for routine determinations of apolipoprotein A-I and B
16. Models for the description and explanation of relative change
17. Paraoxonase polymorphism met-leu 54 is associated with modified serum concentration of the enzyme
18. Glycation impairs high-density lipoprotein function
19. Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease
20. Paraoxonase genotypes, lipoprotein lipase activity, and HDL
21. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia
22. Effects of postmenopausal hormone replacement with oral and transdermal estrogen on high density lipoprotein metabolism
23. Relationship between serum butyrylcholinesterase activity, hypertriglyceridaemia and insulin sensitivity in diabetes mellitus